Gabapentin enacarbil Chemical Properties
- Melting point:65 °C
- Density 1.134
- CAS DataBase Reference478296-72-9(CAS DataBase Reference)
Gabapentin enacarbil Usage And Synthesis
- DescriptionIn April 2011, the U.S. FDA approved gabapentin enacarbil (XP- 13512) for the treatment of moderate-to-severe Restless Legs Syndrome (RLS) in adults. Gabapentin enacarbil is a novel prodrug of gabapentin that was designed to be recognized as a substrate for two high-capacity nutrient transports, monocarboxylate transporter type 1 and sodium-dependent multivitamin transporter, and to be efficiently cleaved after absorption to give gabapentin. The separated enantiomers of gabapentin enacarbil have similar cleavage rates in human tissues. Preclinical studies showed that gabapentin enacarbil provides good systemic exposure of gabapentin in rats and monkeys. Gabapentin enacarbil is prepared as a racemic mixture from gabapentin either by sequential coupling with 1-chloroethyl chloroformate in the presence of trimethylsilyl chloride and triethylamine followed by addition of isobutyric acid or by direct coupling with an activated 1-(isobutyryloxy) ethyl carbonate.
- OriginatorXenoport (United States)
- DefinitionChEBI: A carbamate ester that is the N-[1-(isobutyryloxy)ethoxy]carbonyl derivative of [1-(aminomethyl)cyclohexyl]acetic acid. The prodrug for gabapentin, used for treatment of neuropathic pain and restless legs syndrome.
- brand nameHorizant
- Company Name:LGM Pharma
- Company Name:Shanghai Fuhe Chemistry Technology Co., Ltd.
- Company Name:BOC Sciences
- Company Name:MedChemexpress LLC
- Company Name:GIHI CHEMICALS CO.,LTD